ClinicalTrials.gg
Active, not recruitingNCT02881320Updated Sep 24, 2026

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

A Phase 2/3 interventional study of B/F/TAF (Adult Strength) and B/F/TAF (Low Dose) in HIV-1 Infection, sponsored by Gilead Sciences. Active, not recruiting at 25 sites in 4 countries. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
177
Allocation
Non-randomized
Ages
1 Month to 17 Years
Sex
All
01

Study summary

The goals of this clinical study are to learn how Bictegravir/Emtricitabine/Tenofovir Alafenamide fixed dose combination (FDC) interacts with the body, confirm the dose, and also to learn more about the safety and tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide FDC in adolescents and children with HIV-1.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Cohort 1: -1 infected adolescents (12 to \< 18 years of age and screening weight ≥ 35 kg) who are virologically suppressed for ≥ 6 months prior to screening. Cohort 2: HIV-1 infected children (6 to \< 12 years of age and screening weight ≥ 25 kg) who are virologically suppressed for ≥ 6 months prior to screening.

Cohort 3: HIV-1 infected children (≥ 2 years of age and screening weight of ≥ 14 to \< 25 kg) who are virologically suppressed for ≥ 6 months prior to screening.

Cohort 4 Group 1: HIV-1 infected children (≥ 2 years of age and screening weight of ≥ 14 to \< 25 kg) who are virologically suppressed for ≥ 6 months prior to screening and unable to swallow tablets.

  • Documented plasma HIV-1 ribonucleic acid (RNA) \< 50 copies/mL on a stable regimen (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL) for ≥ 6 months preceding the Screening visit. Unconfirmed virologic elevations of ≥ 50 copies/mL (transient detectable viremia, or "blip") prior to screening are acceptable. If the lower limit of detection of the local HIV-1 RNA assay is \< 50 copies/mL (eg, \< 20 copies/mL), the plasma HIV-1 RNA level cannot exceed 50 copies/mL on two consecutive HIV-1 RNA tests.
  • Stable antiretroviral regimen of 2 nucleoside reverse transcriptase inhibitors (NRTIs) in combination with a third agent for a minimum of 6 months prior to the screening visit. Individuals undergoing dose modifications to their antiretroviral regimen for growth or who are switching medication formulation(s) are considered to be on a stable antiretroviral regimen.
  • Estimated (eGFR) ≥ 90 mL/min/1.73 m\^2 according to the Schwartz Formula.
  • No documented or suspected resistance to emtricitabine (FTC), tenofovir (TFV), or integrase strand transfer inhibitors (INSTIs) including, but not limited to, the reverse transcriptase resistance mutations K65R and M184V/I.

Cohort 4 Group 2-4: HIV-1 infected children (≥ 1 month of age and screening weight of ≥ 3 to \< 14 kg) who are treatment naive or on antiretroviral (ARV) treatment for ≥ 1 month prior to screening.

  • Positive confirmatory HIV test (confirmatory nucleic acid-based testing if \< 18 months of age).
  • On a stable ARV regimen for ≥ 1 month or treatment naive (Individual is considered treatment naive if ARVs were given for prevention of mother-to-child transmission but not for HIV treatment).
  • For \< 1 year of age, eGFR ≥ the minimum normal values for age according to the information below using the Schwartz Formula,

    • 30 mL/min/1.73 m\^2 for age > 4 weeks to ≤ 95 days.
    • 39 mL/min/1.73 m\^2 for age ≥ 96 days to ≤ 6 months.
    • 49 mL/min/1.73 m\^2 for age > 6 months to \< 12 months.
  • For ≥ 1 year of age, eGFR ≥ 90 mL/min/1.73 m\^2 using the Schwartz Formula.
  • No documented or suspected resistance to FTC, TFV, or INSTIs including, but not limited to, the reverse transcriptase resistance mutation K65R.
  • For individuals \< 14 kg, M184V/I AND HIV-1 RNA \< 50 copies/mL will be allowed. Individuals with HIV-1 RNA > 50 copies/mL should not have FTC, TFV, or INSTI resistance mutations.
  • Last dose of nevirapine (NVP) or efavirenz (EFV), if applicable, ≥ 14 days prior to enrollment.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
177 participants (actual)

Study arms

  • Experimental
    Cohort 1 (12 to < 18 years of age and weight ≥ 35 kg)

    * Part A: Participants will participate in an Intensive PK evaluation at Week 2 or Week 4 and continue to receive the adult strength B/F/TAF FDC through Week 48. * Part B: Following confirmation of BIC PK data from Cohort 1 Part A, participants will receive the adult strength B/F/TAF through Week 48.

    Drug: B/F/TAF (Adult Strength)

  • Experimental
    Cohort 2 (6 to < 12 years of age and weight ≥ 25 kg)

    * Part A: Participants will participate in an Intensive PK evaluation at Week 2 or Week 4 and continue to receive the adult strength B/F/TAF FDC through Week 48. * Part B: Following confirmation of BIC PK data from Cohort 2 Part A, participants will receive the adult strength B/F/TAF FDC through Week 48.

    Drug: B/F/TAF (Adult Strength)

  • Experimental
    Cohort 3 (≥ 2 years of age and weight ≥ 14 to < 25 kg)

    * Part A: Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive the low dose B/F/TAF FDC tablet through Week 48. * Part B: Following confirmation of BIC PK data from Cohort 3 Part A, participants will receive the low dose B/F/TAF FDC tablet through Week 48.

    Drug: B/F/TAF (Low Dose)

  • Experimental
    Cohort 4 Group 1 (≥ 2 years of age and weight ≥ 14 to < 25 kg)

    Due to Cohort 3 Part A Intensive PK evaluation at Week 2 with the low dose B/F/TAF FDC tablet, participants will not participate in an Intensive PK evaluation at Week 2. Participants will receive B/F/TAF FDC tablets for oral suspension (TOS) once daily through Week 48.

    Drug: B/F/TAF (TOS)

  • Experimental
    Cohort 4 Group 2 (≥ 1 month of age and weight ≥ 10 to < 14 kg)

    Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive B/F/TAF FDC TOS twice daily through Week 48.

    Drug: B/F/TAF (TOS)

  • Experimental
    Cohort 4 Group 3 (≥ 1 month of age and weight ≥ 6 to < 10 kg)

    Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive B/F/TAF FDC TOS twice daily through Week 48.

    Drug: B/F/TAF (TOS)

  • Experimental
    Cohort 4 Group 4 (≥ 1 month of age and weight ≥ 3 to < 6 kg)

    Participants will participate in an Intensive PK evaluation at Week 2 after which they will continue to receive B/F/TAF FDC TOS twice daily through Week 48.

    Drug: B/F/TAF (TOS)

  • Experimental
    Open-Label Extension

    Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive adult strength B/F/TAF FDC, low dose B/F/TAF FDC, or B/F/TAF FDC TOS (based on age and weight) until it becomes available for use according to the participant's age and weight or the product becomes accessible to participants through an access program.

    Drug: B/F/TAF (Adult Strength) · Drug: B/F/TAF (Low Dose) · Drug: B/F/TAF (TOS)

Interventions

  • DrugB/F/TAF (Adult Strength)

    50/200/25 mg FDC tablets administered orally once daily without regard to food.

    Also known as: Biktarvy®, GS-9883/F/TAF

  • DrugB/F/TAF (Low Dose)

    Drug page: Tenofovir alafenamide

    30/120/15 mg FDC tablets administered orally once daily without regard to food.

    Also known as: GS-9883/F/TAF

  • DrugB/F/TAF (TOS)

    Drug page: Tenofovir alafenamide

    2 x B/F/TAF 15/60/7.5 mg (total daily dose 30/120/15 mg) FDC tablets administered orally as TOS, once daily.

    Also known as: GS-9883/F/TAF

  • DrugB/F/TAF (TOS)

    Drug page: Tenofovir alafenamide

    2 x B/F/TAF 3.75/15/1.88 mg (total daily dose 15/60/7.52 mg) FDC tablets administered orally as TOS, twice daily.

    Also known as: GS-9883/F/TAF

  • DrugB/F/TAF (TOS)

    Drug page: Tenofovir alafenamide

    1 x B/F/TAF 3.75/15/1.88 mg (total daily dose 7.5/30/3.76 mg) FDC tablets administered orally as TOS, twice daily.

    Also known as: GS-9883/F/TAF

  • DrugB/F/TAF (TOS)

    Drug page: Tenofovir alafenamide

    1 x B/F/TAF 1.88/7.5/0.94 mg (total daily dose 3.76/15/1.88 mg) FDC tablets administered orally as TOS, twice daily

    Also known as: GS-9883/F/TAF

06

What researchers measure

Primary outcomes

  1. PK Parameter: AUCtau of Bictegravir

    AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose; Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  2. PK Parameter: Ctau of Bictegravir

    Ctau is defined as the observed drug concentration at the end of the dosing interval. Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose; Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  3. PK Parameter: AUC0-24 of TAF (Cohort 4)

    AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  4. PK Parameter: AUC0-24 of Bictegravir (Cohort 4)

    AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  5. PK Parameter: Cmax of TAF (Cohort 4)

    Cmax is defined as maximum observed concentration of drug. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  6. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 24

    Time frame: Up to 24 weeks

  7. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 24

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Proportion of Participants with Plasma HIV-1 RNA < 50 copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm

    Time frame: Week 24

  2. Proportion of Participants with Plasma HIV-1 RNA < 50 copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

    Time frame: Week 48

  3. Change from Baseline in CD4+ Cell Counts at Week 24

    Time frame: Baseline, Week 24

  4. Change from Baseline in CD4+ Cell Counts at Week 48

    Time frame: Baseline, Week 48

  5. Change from Baseline in CD4+ Cell Count Percentages at Week 24

    Time frame: Baseline, Week 24

  6. Change from Baseline in CD4+ Cell Count Percentages at Week 48

    Time frame: Baseline, Week 48

  7. PK Parameter: Tmax of Bictegravir

    Tmax is defined as the time (observed time point) of Cmax. Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose; Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  8. PK Parameter: Cmax of Bictegravir

    Cmax is defined as the maximum observed concentration of drug. Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose; Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  9. PK Parameter: AUClast of Bictegravir

    AUClast is defined as the area under the concentration of drug from time zero to the last observable concentration. Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose; Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  10. PK Parameter: T1/2 of Bictegravir

    T1/2 is defined as the estimate of the terminal elimination half-life of the drug. Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose; Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  11. PK Parameter: Apparent Clearance (CL) of Bictegravir

    CL is defined as the systemic clearance of the drug following study drug administration. Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose; Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  12. PK Parameter: Apparent Vz of Bictegravir

    Vz is defined as the volume of distribution of the drug after study drug administration. Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose; Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  13. PK Parameter: AUCtau of TAF and FTC

    AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose; Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  14. PK Parameter: AUClast of TAF and FTC (Cohorts 1, 2, and 3)

    AUClast is defined as the area under the concentration of drug from time zero to the last observable concentration. Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose

  15. PK Parameter: AUClast of FTC (Cohorts 4)

    AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  16. PK Parameter: Cmax of TAF and FTC (Cohorts 1, 2, and 3)

    Cmax is defined as the maximum observed concentration of drug. Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose

  17. PK Parameter: Cmax of FTC (Cohorts 4)

    Cmax is defined as maximum observed concentration of drug. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  18. PK Parameter: Ctau of TAF and FTC

    Ctau is defined as the observed drug concentration at the end of the dosing interval. Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose; Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  19. PK Parameter: Tmax of TAF and FTC

    Tmax is defined as the time (observed time point) of Cmax. Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose; Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  20. PK Parameter: T1/2 of TAF and FTC

    T1/2 is defined as the estimate of the terminal elimination half-life of the drug. Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose; Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  21. PK Parameter: Apparent CL of TAF and FTC

    CL is defined as the systemic clearance of the drug following study drug administration. Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose; Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  22. PK Parameter: Apparent Vz of TAF and FTC

    Vz is defined as the volume of distribution of the drug after study drug administration. Cohorts 1 \& 2 Part A will participate in an Intensive PK Evaluation at Week 2 or Week 4. Samples will be collected at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post-dose. Cohort 3 Part A will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose. Cohort 4 Groups 2, 3, and 4 participants will participate in an Intensive PK evaluation at Week 2. Samples will be collected at 0 (pre-dose) 0.5, 1, 2, 4, and 8 hours post-dose.

    Time frame: Week 2 or Week 4 for Cohorts 1 & 2: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, & 24 hours postdose; Week 2 for Cohort 3: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, & 24 hours post-dose; Week 2 for Cohort 4: 0 (predose) 0.5, 1, 2, 4, & 8 hours postdose

  23. Percentage of Participants Experiencing Treatment-Emergent Adverse Events Through Week 48

    Time frame: Up to 48 weeks

  24. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 48

    Time frame: Up to 48 weeks

  25. Acceptability of B/F/TAF Formulation at Day 1 (All Cohorts)

    Participants or legal guardian will be asked: * if study drug shape and size were acceptable (for Cohort 1 and Cohort 2) * about ease of swallowability and the shape and size of study drug when swallowed (for Cohort 3) * about their understanding of instructions, preparation of the study drug formulation and study drug administration and taste (for Cohort 4)

    Time frame: Day 1

  26. Palatability of B/F/TAF Formulation at Day 1 (All Cohorts)

    Participants or legal guardian will be asked about the study drug taste (All Cohorts)

    Time frame: Day 1

  27. Acceptability of B/F/TAF Formulation at Week 4 (All Cohorts)

    Participants or legal guardian will be asked: * if study drug shape and size were acceptable (for Cohort 1 and Cohort 2) * about ease of swallowability and the shape and size of study drug when swallowed (for Cohort 3). * about their understanding of instructions, preparation of the study drug formulation and study drug administration and taste (for Cohort 4)

    Time frame: Week 4

  28. Palatability of B/F/TAF Formulation at Week 4 (All Cohorts)

    Participants or legal guardian will be asked about the study drug taste (All Cohorts)

    Time frame: Week 4

  29. Acceptability of B/F/TAF Formulation at Week 24 (Cohort 3 and Cohort 4)

    Participants or legal guardian will be asked: * about ease of swallowability and the shape and size of study drug when swallowed (for Cohort 3). * about their understanding of instructions, preparation of the study drug formulation and study drug administration and taste (for Cohort 4)

    Time frame: Week 24

  30. Palatability of B/F/TAF Formulation at Week 24 (Cohort 3 and Cohort 4)

    Participants or legal guardian will be asked about the study drug taste

    Time frame: Week 24

  31. Acceptability of B/F/TAF Formulation at Week 48 (Cohort 3 and Cohort 4)

    Participants or legal guardian will be asked: * about ease of swallowability and the shape and size of study drug when swallowed (for Cohort 3). * about their understanding of instructions, preparation of the study drug formulation and study drug administration and taste (for Cohort 4)

    Time frame: Week 48

  32. Palatability of B/F/TAF Formulation at Week 48 (Cohort 3 and Cohort 4)

    Participants or legal guardian will be asked about the study drug taste

    Time frame: Week 48

  33. Acceptability of B/F/TAF Formulation at Week 1 (Cohort 4)

    Participants or legal guardian will be asked about their understanding of instructions, preparation of the study drug formulation and study drug administration and taste

    Time frame: Week 1

  34. Palatability of B/F/TAF Formulation at Week 1 (Cohort 4)

    Participants or legal guardian will be asked about the study drug taste

    Time frame: Week 1

  35. Acceptability of B/F/TAF Formulation at Week 2 (Cohort 4)

    Participants or legal guardian will be asked about their understanding of instructions, preparation of the study drug formulation and study drug administration and taste

    Time frame: Week 2

  36. Palatability of B/F/TAF Formulation at Week 2 (Cohort 4)

    Participants or legal guardian will be asked about the study drug taste

    Time frame: Week 2

07

Study locations

25 sites
  • Children's National Health System
    Washington D.C., District of Columbia 20010, United States
  • Midway Immunology and Research Center
    Ft. Pierce, Florida 34982, United States
  • University of Florida Health
    Gainesville, Florida 32209, United States
  • USF Clinic at Children's Medical Services (study visits and drug storage)
    Tampa, Florida 33606, United States
  • Grady Health System Ponce Center Family and Youth Clinic
    Atlanta, Georgia 30322, United States
  • Wayne Pediatric Clinic
    Detroit, Michigan 48201, United States
  • Bellevue Hospital
    New York, New York 10016, United States
  • Duke Children's Health Center, Pediatric Infectious Diseases
    Durham, North Carolina 27710, United States
  • St. Christopher's Hospital for Children/Section of Immunology
    Philadelphia, Pennsylvania 19134, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Department of Paediatrics and Child Health
    Bloemfontein, 9301, South Africa
  • Be Part Ypluntu Centre
    Cape Town, 7646, South Africa
  • FAMCRU, Ward J8
    CapeTown, 7505, South Africa
  • Dr. J Fourie Medical Centre
    Dundee, 3000, South Africa
  • Enhancing Care Foundation, Durban International Clinical Research Site
    Durban, 4302, South Africa
  • Wits RHI Shandukani Research Centre, Wits Reproductive Health & HIV Institute
    Johannesburg, 2038, South Africa
  • Empilweni Service and Research Unit (ESRU)
    Johannesburg, 2112, South Africa
  • VX Pharma(Pty) Ltd
    Pretoria, 0087, South Africa
  • Perinatal HIV Research Unit
    Soweto, 2013, South Africa
  • The HIV Netherlands Australia Thailand Research Collaboration
    Bangkok, 10330, Thailand
  • Faculty of Medicine Siriraj Hospital, Mahidol University
    Bangkok, 10700, Thailand
  • Faculty of Medicine, Khon Kaen University
    Khon Kaen, 40002, Thailand
  • Makerere University, Johns Hopkins (MU-JHU) Research Collaboration
    Kampala, 0000, Uganda
  • Joint Clinical Research Centre
    Kampala, 10005, Uganda
  • Baylor College of Medicine Children's Foundation - Uganda
    Kampala, Uganda
08

References and documents

Publications

  • Rodriguez CA, Natukunda E, Strehlau R, Venter EL, Rungmaitree S, Cunningham CK, Lalloo U, Kosalaraksa P, HellstrOm E, Liberty A, McGrath EJ, Kaur M, Leisegang R, Hindman JT, Vieira VA, Kersey K, Cotton MF, Rakhmanina N, Gaur AH. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study. Lancet HIV. 2024 May;11(5):e300-e308. doi: 10.1016/S2352-3018(23)00327-2. Epub 2024 Apr 12. PubMed 38621393 ↗
  • Gaur AH, Cotton MF, Rodriguez CA, McGrath EJ, Helstrom E, Liberty A, Natukunda E, Kosalaraksa P, Chokephaibulkit K, Maxwell H, Wong P, Porter D, Majeed S, Yue MS, Graham H, Martin H, Brainard DM, Pikora C. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. Lancet Child Adolesc Health. 2021 Sep;5(9):642-651. doi: 10.1016/S2352-4642(21)00165-6. Epub 2021 Jul 22. PubMed 34302760 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Mar 2025, 102 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2016
First posted
Aug 26, 2016
StartActual
Sep 21, 2016
Primary completionActual
Mar 24, 2025
CompletionEst.
Jun 2027
Results delay requested
Feb 12, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02881320
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 26, 2016
Start date
Sep 21, 2016
Primary completion
Mar 24, 2025
Completion
Jun 2027 (estimated)
Last update
Sep 24, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir alafenamide

Start the discussion